Safety, tolerability, pharmacokinetics, and efficacy of SHR-A1811, an antibody- drug conjugate, in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC): a multicenter, open-label, phase 1/2 study

被引：2
|
作者：
Lu, Shun
Jian, Hong
Hong, Wei
Song, Zhengbo
Yang, Nong
Hu, Sheng
Liang, Zibin
Wang, Yongsheng
Wang, Yan
Peng, Min
Yu, Yan
Li, You
Shuang, Jiapeng
Zhao, Kaijing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2023-CT204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT204
引用
收藏
页数：3
相关论文
共 50 条
  • [1] SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study
    Li, Ziming
    Song, Zhengbo
    Hong, Wei
    Yang, Nong
    Wang, Yongsheng
    Jian, Hong
    Liang, Zibin
    Hu, Sheng
    Peng, Min
    Yu, Yan
    Wang, Yan
    Jiao, Zicong
    Zhao, Kaijing
    Song, Ke
    Li, You
    Shi, Wei
    Lu, Shun
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [2] Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial
    Fang, Wenfeng
    Zhao, Yuanyuan
    Huang, Yan
    Zhang, Yaxiong
    Hong, Shaodong
    Huang, Yihua
    Zhao, Hongyun
    Yang, Yunpeng
    Zhao, Shen
    Chen, Gang
    Zhou, Huaqiang
    Ma, Yuxiang
    Zhou, Ningning
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Li, Xingya
    Huang, Siyuan
    Wu, Jingxun
    Li, Yibin
    Chang, Baoping
    Hu, Sheng
    Yang, Shujun
    Xu, June
    Van, Hardy
    Zhi, Lihua
    Xia, Yue
    Yang, Fei
    Xia, Yi
    Kong, Paul
    Dong, Wei
    Xu, Ting
    Zhang, Li
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [4] Safety and efficacy results of a phase IV, open-label, multicenter, safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (NSCLC): ISAFE study.
    Tan, Fenlai
    Gu, Aiqin
    Zhang, Yiping
    Jiao, Shun Chang
    Wang, Chang-Li
    He, Jintao
    Jia, Xueke
    Zhang, Li
    Peng, Jiewen
    Wu, Meina
    Ying, Kejing
    Wang, Junye
    Ma, Kewei
    Zhang, Shucai
    You, Changxuan
    Ding, Lieming
    Wang, Yinxiang
    Shen, Haijiao
    Wan, Jiang
    Sun, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Genomic landscape and efficacy of HER2-targeted therapy in patients with HER2-mutant non-small cell lung cancer
    Han, Yanjie
    Xiong, Yuanyuan
    Lu, Tao
    Chen, Rongrong
    Liu, Yuan
    Tang, Hui
    Geng, Ruixuan
    Wang, Yingyi
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [6] A multicenter, open-label, phase IIIB trial of erlotinib in patients with advanced non-small cell lung cancer
    Hainsworth, J
    Spigel, D
    O'Neill, V
    Klencke, B
    LUNG CANCER, 2005, 49 : S246 - S247
  • [7] Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial
    Ulys, Albertas
    Jankevicus, Feliksas
    Jievaltas, Mindaugas
    Venckus, Raimundas
    Auskalnis, Stasys
    Kardelis, Zygimantas
    Barisiene, Marija
    Maclean, Carol M.
    van Os, Steve
    Larsen, Finn
    PROSTATE, 2024, 84 (06): : 584 - 598
  • [8] Vandetanib with pemetrexed in patients with previously treated non-small cell lung cancer (NSCLC): An open-label, multicenter phase I study
    De Boer, R.
    Vansteenkiste, J.
    Humblet, Y.
    Wolf, J.
    Nogova, L.
    Ruffert, K.
    Smith, R.
    Godwood, A.
    Milenkova, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [9] Phase ib study of safety, tolerability and pharmacokinetics of simotinib in patients with advanced non-small cell lung cancer
    Hu, Xingsheng
    Han, Xiaohong
    Zhang, Li
    Ding, Yanhua
    Wang, Hanping
    Mu, Hua
    Sun, Yan
    Shi, Yuankai
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC)
    Khatri, Amit
    Cobbina, Enoch
    Cheng, Shen
    Abutarif, Malaz
    Garimella, Tushar
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345